摘要
由新型冠状病毒(SARS⁃CoV⁃2)引起的新型冠状病毒感染(COVID⁃19)的大流行带来了一场全球性公共卫生危机。疫苗的成功研发及人群广泛接种虽可使SARS⁃CoV⁃2感染者出现症状、重症、危重症以及死亡的人数显著减少,但疫苗的效力还会受到病毒进化和新变种出现的影响。因此,COVID⁃19的防治不能仅靠疫苗,仍需有效的抗病毒治疗药物以阻止疾病的进展。抗病毒药物可在SARS⁃CoV⁃2感染的各个阶段提供帮助,这包括暴露前或暴露后的预防、早期治疗和晚期治疗。在本篇综述中,我们总结了针对SARS⁃CoV⁃2已上市及还处于临床试验期的小分子抗病毒药物的研究文献,讨论了这些小分子抗病毒药物治疗SARS⁃CoV⁃2感染的有效性以及安全性,并对未来小分子抗病毒药物的发展作出了展望。
The pandemic of COVID⁃19 caused by SARS⁃CoV⁃2 infection has brought a global public health crisis.Although the successful development and widespread vaccination can significantly reduce the number of people infected with SARS⁃CoV⁃2 who experience symptoms,severe illness,critical illness,and death,the effectiveness of vaccines is affected by the evolution of the virus and the emergence of new variants.Therefore,the prevention and treatment of COVID⁃19 cannot only rely on vaccines,and effective anti⁃viral treatment drugs are still needed to prevent the progression of the disease.Anti⁃viral drugs can assist in all stages of SARS⁃CoV⁃2 infection,including pre⁃or post⁃exposure prevention,early treatment,and advanced treatment.In this review,we summarize the research literature on small molecular anti⁃viral drugs that have been marketed and are still in clinical trials against SARS⁃CoV⁃2,discuss the effectiveness and safety of these small molecular anti⁃viral drugs in the treatment of COVID⁃19,and make a prospect for the development of small molecular anti⁃viral drugs in the future.
作者
王鲁文
范慧
陈国忠
WANG Luwen;FAN Hui;CHEN Guozhong(Dept.of Infectious Diseases,Renmin Hospital of Wuhan University,Wuhan 430060,Hubei,China;Dept.of Respiratory and Critical Care Medicine,Renmin Hospital of Wuhan University,Wuhan 430060,Hubei,China)
出处
《武汉大学学报（医学版）》
CAS
2023年第9期1068-1077,共10页
Medical Journal of Wuhan University
作者简介
同第一作者:王鲁文,男,1975-,医学博士,副主任医师,主要从事传染病学研究,E-mail:wangluw8253@163.com;同第一作者:范慧,女,1983-,医学硕士,副主任护师,主要从事呼吸危重症治疗与护理及护理管理研究,E-mail:421461960@qq.com;通讯作者:陈国忠,男,1963-,医学硕士,主任医师,主要从事呼吸危重症研究,E-mail:guozhongch6389@163.com。
